Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics to Participate in BIO Digital Conference
04:15pm, Wednesday, 09'th Jun 2021
AUSTIN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., Presid
PSTV Stock: From $2.60 To $2.84 (9.23% Increase) Pre-Market Explanation
08:46am, Tuesday, 04'th May 2021
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) went from $2.60 to $2.84 (up 9.23%) pre-market. This is why it happened.
Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
07:30am, Tuesday, 04'th May 2021
– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript
07:55am, Friday, 23'rd Apr 2021
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript
Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
04:05pm, Thursday, 22'nd Apr 2021
Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
07:30am, Thursday, 08'th Apr 2021
AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized the
PSTV Stock Price Increases Over 40% Pre-Market: Why It Happened
07:59am, Tuesday, 23'rd Mar 2021
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 40% pre-market. This is why it happened.
Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in developmen
Plus Therapeutics to Participate in Upcoming Virtual Conferences
07:30am, Wednesday, 03'rd Mar 2021
AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript
09:10pm, Monday, 22'nd Feb 2021
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
04:05pm, Monday, 22'nd Feb 2021
– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –
Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021
04:15pm, Thursday, 11'th Feb 2021
AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized ther
Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference
07:30am, Thursday, 11'th Feb 2021
AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therap
Plus Therapeutics to Participate in Upcoming January Conferences
04:15pm, Tuesday, 05'th Jan 2021
AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ann
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
07:30am, Tuesday, 15'th Dec 2020
AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized thera
